Therapeutic Science and Strategy

During this episode, Lumanity experts Rob Rawlinson and Kate Goacher discuss insights and takeaways from their recent attendance at the 2024 European Society for Medical Oncology (ESMO) conference. Their conversation covers a variety of topics, including:

• The importance of the patient and including the patient voice in drug development
• The way that Artificial Intelligence (AI) could impact and innovate cancer care
• Insights on a selection of early-phase extensive-stage small-cell lung cancer (ES-SCLC) assets

In this episode, we talk about the concerns, misconceptions, and the value of engaging directly with and including the pediatric voice in market research

In our latest Lumanity bitesize podcast, we explore how to avoid the common challenges and pitfalls encountered in communication testing research, and share best practices in applying a behavioural science lens to bring about stakeholder behaviour change.

Our discussion includes:

• The importance of evaluating concepts using the right criteria
• Generating maximum impact using clear and simple ads that cut through the noise
• Being vigilant that the insights being used are robust and precise - and ultimately fuel better campaign decisions
• The importance of engaging with the target audience early and ensuring campaigns are designed around a common unmet need
• Specificity required in bringing about behavioural change and how best to align to a clear communication objective

In this special podcast episode in honor of Rare Disease Day 2024, Angela Wheeler, President of Insight at Lumanity and Dr. Karin Hoelzer, Director of Policy and Regulatory Affairs at the National Organization for Rare Disorders (NORD), discuss opportunities for pharmaceutical companies to work with and support rare disease communities. Learn how NORD is strengthening collaboration between pharmaceutical companies and rare disease communities, and examples of the positive impact that can be made when pharmaceutical companies, organizations like NORD, and patient advocates join together. Listen to the full episode to hear Angela ask Karin some important questions, including:

• What are the biggest opportunities for the rare disease communities in 2024?
• What are some lessons learned for fruitful collaboration between pharma companies and rare disease communities and organizations like NORD?
• What policy priorities is NORD focused on in 2024?
• What role can patient advocates and pharma play in supporting the rare disease community on these issues?

In this podcast episode, we explore the rich potential of social media listening (SML) insights, and how, when interpreted and acted on, they can have a significant impact on commercial decision-making.

Hear from Lumanity experts as they bring SML to life using several real world examples. Topics include:

• How the agility, flexibility and insights from SML research are being harnessed to help improve commercial decisions
• How SML best complements traditional research and data
• The value of SML in reaching conversation leaders, HCPs and patient advocates
• The value for detecting commonalities and patterns, as well as perception changes over time
• How to ensure these insights are actionable - and what not to do

In this podcast episode, we explore the fascinating world of artificial intelligence and its impact on the healthcare industry, as well as the ever evolving realm of research and its potentially transformative power on decision making.

Hear from Lumanity experts Damian Eade, Head of Digital Insights and Analytics, Gemma Spickernell, Director of Behavioral Science, and Andrew Wood, Head of Behavioral Science as they discuss how to navigate the balance between the benefits of AI while ensuring accuracy and integrity in research. This thought-provoking conversation considers the potential of Generative AI, it's application and implications in the near term, including:

• The potential creative capabilities of Generative AI and the implications for enhancing efficiency
• The strategic integration of insights from various sources to drive decision-making
• The critical role of researchers in maintaining the values and integrity of research

There are incredible synergies with joint HEOR and Real World Evidence (RWE) projects, but there are also unique challenges. In this podcast episode, The Importance of RWE Strategy Planning, Ann-Marie Chapman, Nikita Jeswani, Meena Venkatachalam, and Alex Thorel discuss the use cases and planning for RWE, identifying appropriate RWE, and RWE trends. Listen to this podcast to learn:

· Key considerations, steps, and recommendations in identifying appropriate data sources

· Where RWD and RWE are leveraged most across the product lifecycle

· The length of time it takes to initiate an RWE study

· The common mistakes in RWE study planning

· The major changes in the RWD space over the last 10 years and in the future

Strategic risk is often overlooked within the pharmaceutical industry. There's a perception that someone else is picking up the risk ball. Or there is more of a focus on internal risks, with little thought to the larger external factors that can have a significant impact on your launch. We see common risks arise from competitor launches, multi-indication launches, and supply chain issues. Unmitigated risks can lead to costly delays. So, what can you do to identify the risks for your asset launch and successfully mitigate them? In our latest Launch Excellence Alchemy podcast, our team of experts discuss and share their thoughts, tips, and solutions, with a focus on:

• The common strategic risks that arise during the launch of an asset
• Why it's important to create a strategic risk system to monitor these risks
• Creating an appropriate plan to mitigate risks and identifying who is accountable

Join John Crick, Launch Excellence Project Lead, Penny Matthews, Managing Consultant for Ignite™, and Andrew Coates, Risk Management Expert as they share ideas to think outside the box when it comes to risk management.

We know that effective collaboration across cross-functional and global/local launch teams is one of the critical elements to launch success – but teams often struggle to develop the right behaviors that foster a truly collaborative culture. Leadership styles too play a vital role, with research directing us away from 'leading from the front', towards a model that champions interdependent leadership and shared accountability.

In the second episode of our series on launch excellence, we explore how:

• Heroic leadership styles can hinder collaboration when launching a product
• Looking at your own behaviors and mindset can create the biggest catalyst for change in driving collaboration
• External partners and a 'third voice' can be critical in your journey to fostering collaboration

Join Lumanity staff Tracey Barnes, Vice President of Launch Excellence, and Ollie Roberts, a Pharma Launch Expert, as they share their experience and define the critical steps to becoming a more effective launch collaborator.

In this episode, Dr. Nancy McGee and Rob Rawlinson discuss potential implications of the Inflation Reduction Act (IRA) legislation that was passed in the U.S. in 2022.

This episode covers:

• An overview of the IRA in relation to healthcare
• The potential impacts for oncology patients, manufacturers, and oncologists
• The impact of the legislation outside of the U.S.

Speakers:

• Nancy McGee, JD, MPH, DrPH, Senior Vice President, Health Policy & Public Payers, Lumanity
• Rob Rawlinson, Director, Oncology Insights Lead, Lumanity

©2023 Lumanity Inc.